Trianni, Inc.

Trianni, Inc. is a biotechnology company focused on the development of antibody-based therapies using advanced technology to address various health conditions effectively. Trianni, Inc. was founded in 2010 and is headquartered in San Francisco, US.

The company specializes in providing innovative solutions in the field of antibody development. In November 2020, Trianni was acquired by AbCellera Biologics Inc. for USD 90. 00 mn.

The deal was led by AbCellera Biologics Inc. , with participation from investors including Bill & Melinda Gates Foundation and the University of Minnesota. Trianni, Inc. focuses on the development of investigational monoclonal antibody therapies.

Their key offerings include treatments for endocrine disorders and immunological diseases, with notable products such as ABCL635 for vasomotor symptoms related to menopause and ABCL575 for atopic dermatitis, currently undergoing various phases of clinical trials. Trianni, Inc. collaborates with biopharmaceutical companies, generating revenue through research and development agreements. These partnerships involve fee-for-service contracts and milestone-based payments that align with clinical development phases, creating a shared investment model in new therapy developments.

Going forward, Trianni, Inc. plans to expand its product pipeline and enter new international markets while leveraging the USD 90. 00 mn acquired through its recent funding round. This investment is expected to support the advancement of their investigational therapies and facilitate expansion efforts in North America and beyond, aiming for completion of current projects and additional market entries by 2022.